Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

Merck & Co – known as MSD outside of the US and Canada – has unveiled a new cost-cutting plan aimed at saving $3bn every year by the end of 2027.

Merck (MRK) recently revised its 2025 sales guidance to a range of $64.3 billion to $65.3 billion, acknowledging a slight foreign exchange impact, while also announcing lower year-over-year earnings ...

In many ways, despite what RFK Jr. and Rep. Paul Gosar claim, the Vaccine Injury Compensation Program is more friendly to ...

Merck (MRK) announced a bold cost-cutting strategy aiming to save $3 billion annually by 2027, reflecting a major operational ...

As top funds bet big on AI stocks Nvidia and Palantir, they also scooped up Veeva stock as it teases a breakout.

Bristol Myers Squibb (BMY) is gearing up for its earnings release this Thursday. Historically, the stock's one-day ...